Naproxen chemoprevention induces proliferation of cytotoxic lymphocytes in Lynch Syndrome colorectal mucosa

BACKGROUND: Recent clinical trial data from Lynch Syndrome (LS) carriers demonstrated that naproxen administered for 6-months is a safe primary chemoprevention that promotes activation of different resident immune cell types without increasing lymphoid cellularity. While intriguing, the precise immu...

Descripción completa

Detalles Bibliográficos
Autores principales: Bowen, Charles M., Deng, Nan, Reyes-Uribe, Laura, Parra, Edwin Roger, Rocha, Pedro, Solis, Luisa M., Wistuba, Ignacio I., Sepeda, Valerie O., Vornik, Lana, Perloff, Marjorie, Szabo, Eva, Umar, Asad, Sinha, Krishna M., Brown, Powel H., Vilar, Eduardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10189148/
https://www.ncbi.nlm.nih.gov/pubmed/37207208
http://dx.doi.org/10.3389/fimmu.2023.1162669

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10189148/
https://www.ncbi.nlm.nih.gov/pubmed/37207208
http://dx.doi.org/10.3389/fimmu.2023.1162669

Ejemplares similares